Company news
Harrow, Inc. news in 2026
Harrow, Inc.'s news releases, calls and decks from 2026, newest first.
Harrow to Participate in Two Investor Conferences in November
November 12, 2026
Q3-2026 Letter to Stockholders
November 9, 2026
Harrow Announces Third Quarter 2026 Financial Results
November 9, 2026
Harrow Launches HarrowRx Platform
November 2, 2026
Harrow To Report Third Quarter 2026 Financial Results After Market Close on November 9, 2026
October 26, 2026
Harrow Closes Acquisition of TYRVAYA®
October 5, 2026
Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO
September 30, 2026
Harrow to Participate in Three Investor Conferences in September
September 1, 2026
Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections
August 20, 2026
Harrow Announces Second Quarter 2026 Financial Results
August 10, 2026
Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease
August 6, 2026
Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026
July 27, 2026
Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting
July 20, 2026
Harrow Announces Commercial Launch of BYOOVIZ® in the United States
July 1, 2026
Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare
June 10, 2026
Harrow to Present at William Blair’s 46th Annual Growth Stock Conference
May 26, 2026
Harrow Announces First Quarter 2026 Financial Results
May 11, 2026
Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026
April 27, 2026
Harrow Announces the Issuance of J-Code for IOPIDINE® 1%
April 15, 2026
Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030
March 23, 2026
Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth
March 23, 2026
Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting
March 17, 2026
Harrow to Present at Leerink Partner’s 2026 Global Healthcare Conference
March 3, 2026
Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication
March 2, 2026
Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance
March 2, 2026
Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026
February 18, 2026
Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits
February 17, 2026
OSRX Confirms Ongoing Licensing and Availability of Compounded Ophthalmic Medications in California
February 3, 2026
Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth
February 1, 2026
Calls in 2026
Decks in 2026
- Jefferies Global Healthcare Conference 2026
Conference · 22 slides · Nov 16, 2026
- Q3 2026 Earnings Presentation
Earnings · 30 slides · Nov 10, 2026
- Q2 2026 Earnings Presentation
Earnings · 34 slides · Aug 11, 2026
- William Blair 46th Annual Growth Stock Conference 2026
Conference · 25 slides · Jun 3, 2026
- Q1 2026 Earnings Presentation
Earnings · 30 slides · May 12, 2026
- Leerink Partners conference (March 2026)
Conference · 20 slides · Mar 10, 2026
- Q4 2025 Earnings Presentation
Earnings · 32 slides · Mar 3, 2026